Compounds and methods for modulating apoptosis

Details Compounds and methods for modulating apoptosis Compounds and methods for modulating apoptosis

1999-02-10

2003-05-13

Brumback, Brenda (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S009100, C530S317000

Reexamination Certificate

active

06562786

ABSTRACT:

TECHNICAL FIELD
The present invention relates generally to methods for methods for modulating cadherin mediated processes, and more particularly to the use of cyclic peptides comprising a classical cadherin cell adhesion recognition sequence for inducing apoptosis in cadherin-expressing cells.
BACKGROUND OF THE INVENTION
Cancer is a significant health problem throughout the world. Although advances have been made in detection and therapy of cancer, no vaccine or other universally successful method for prevention or treatment is currently available. For example, among women, breast and ovarian cancer are prevalent in the United States and other countries. Breast cancer, in particular, remains the second leading cause of cancer-related deaths in women, affecting more than 180,000 women in the United States each year. For women in North America, the life-time odds of getting breast cancer are now one in eight. Management of the disease currently relies on a combination of early diagnosis (through routine breast screening procedures) and aggressive treatment, which may include one or more of a variety of treatments such as surgery, radiotherapy, chemotherapy and hormone therapy.
Prostate cancer is the most common form of cancer among males, with an estimated incidence of 30% in men over the age of 50. Human prostate cancer has the propensity to metastasize to bone. Treatment is commonly based on surgery and/or radiation therapy, but these methods are ineffective in a significant percentage of cases, and this prevalent disease is currently the second leading cause of cancer death among men in the U.S.
To provide improved treatments for such diseases, agents that kill cancer cells are needed. Accordingly, there is a need in the art for compounds that induce apoptosis in cancer cells. The present invention fulfills this need and further provides other related advantages.
SUMMARY OF THE INVENTION
The present invention provides cyclic peptides and methods for modulating cadherin-mediated functions and inducing apoptosis in cadherin-expressing cells. Within one aspect, the present invention provides cyclic peptides comprising the sequence His-Ala-Val. Within one embodiment a cyclic peptide has the formula:
wherein X
1
, and X
2
are optional, and if present, are independently selected from the group consisting of amino acid residues and combinations thereof in which the residues are linked by peptide bonds, and wherein X
1
and X
2
independently range in size from 0 to 10 residues, such that the sum of residues contained within X
1
and X
2
ranges from 1 to 12; wherein Y
1
and Y
2
are independently selected from the group consisting of amino acid residues, and wherein a covalent bond is formed between residues Y
1
and Y
2
; and wherein Z
1
and Z
2
are optional, and if present, are independently selected from the group consisting of amino acid residues and combinations thereof in which the residues are linked by peptide bonds. Such cyclic peptides may comprise modifications such as an N-acetyl or N-alkoxybenzyl group and/or a C-terminal amide or ester group. Cyclic peptides may be cyclized via, for example, a disulfide bond; an amide bond between terminal functional groups, between residue side-chains or between one terminal functional group and one residue side chain; a thioether bond or &dgr;
1
&dgr;
1
-ditryptophan, or a derivative thereof.
Within further aspects, the present invention provides modulating agents that comprise a cyclic peptide as described above. Within specific embodiments, such modulating agents may be linked to one or more of a targeting agent, a drug, a solid support or a support molecule. In addition, or alternatively, a cell adhesion modulating agent may further comprising one or more of: (a) a cell adhesion recognition sequence that is bound by an adhesion molecule other than a cadherin, wherein said cell adhesion recognition sequence is separated from any HAV sequence(s) by a linker; and/or (b) an antibody or antigen-binding fragment thereof that specifically binds to a cell adhesion recognition sequence bound by an adhesion molecule other than a cadherin.
The present invention further provides pharmaceutical compositions comprising a cell adhesion modulating agent as described above, in combination with a pharmaceutically acceptable carrier. Such compositions may further comprise a drug. Alternatively, or in addition, such compositions may comprise: (a) a modulator of cell adhesion comprising a cell adhesion recognition sequence that is bound by an adhesion molecule other than a classical cadherin; and/or (b) an antibody or antigen-binding fragment thereof that specifically binds to a cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin.
Within further aspects, methods are provided for inducing apoptosis in a cadherin-expressing cell, comprising contacting a cadherin-expressing cell with a cell adhesion modulating agent as described above. Within certain embodiments, the cadherin-expressing cell may be a cancer cell, and such cells may be present in a patient.
These and other aspects of the invention will become evident upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each were individually noted for incorporation.


REFERENCES:
patent: 5231082 (1993-07-01), Schasteen
patent: 5352667 (1994-10-01), Lider et al.
patent: 5510628 (1996-04-01), Georger, Jr. et al.
patent: 5585351 (1996-12-01), Ranscht
patent: 5591432 (1997-01-01), Bronson et al.
patent: 5610281 (1997-03-01), Brenner
patent: 5646250 (1997-07-01), Suzuki
patent: 5665590 (1997-09-01), Yang
patent: 406 428 (1991-01-01), None
patent: WO 91/04745 (1991-04-01), None
patent: WO 92/08731 (1992-05-01), None
patent: WO 94/11401 (1994-05-01), None
patent: WO 96/40781 (1996-12-01), None
patent: WO 97/07209 (1997-02-01), None
patent: WO 98/02452 (1998-01-01), None
patent: WO 98/45319 (1998-10-01), None
patent: WO 99/33875 (1999-07-01), None
Kini et al. “A Common Structural Feature Enclosing Interaction Sites: Prediction of Protein-Protein Interaction Sites and Development of Potent Bioactive Peptides” Current Topics in Peptide & Protein Research, I, pp 297-311, 1994.*
Brecknell et al., “Bridge grafts of Fibroblast Growth Factor-4-Secreting Schwannoma Cells Promote Functional Axonal Regeneration in the Nigrostriatal Pathway of the Adult Rat,”Neuroscience 74(3): 775-784, 1996.
Ghirnikar and Eng, “Astrocyte-Schwann Cell Interactions in Culture,”GLIA 11: 367-377, 1994.
Orr, “Angiogenesis Research Offers New Approaches to Treatment of Disease,”Genetic Engineering News, pp. 15-16, 42, May 1, 1996.
Blaschuk et al., “A novel cadherin antagonist (Exherin) blocks human ovarian tumor growth in nude mice,”Molecular Biology of the Cell 10: 72A, Nov. 1999.
Starzinsky-Powitz, E.A., “The putative role of cell adhesion molecules in endometrisis: can we learn from tumour metastasis?,”Mol. Med. Today 5(7): 304-309, 1999.
Williams, E.A., “A novel family of cyclic peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motif,”J. Biol. Chem. 275(6): 4007-4012, Feb. 11, 2000.
Ngo et al., ‘Computational Complexity, Potein Structure Prediction, And The Levinthal Paradox,’ The Protein Folding Problem and Tertiary Structuer Prediction. Ed. K. Merz and L. Le Grand. BirkHauser, Boston MA. pp. 491-495.
Rudinger, J. (1976). Peptide Hormones (ed. J.A. Parsons). University Park Press. Baltimore. pp 1-7.
Berendsen, Herman. ‘A Glimpse Of The Holy Grainl?’ Science, vol. 282, pp. 642-643. Oct. 23, 1998.
Alexander et al., “An N-Cadherin-Like Protein Contributes to Solute Barrier Maintenance in Cultured Endothelium,”Journal of Cellular Physiology 156: 610-618, 1993.
Ali et al., “Conformationally Constrained Peptides and Semipeptides Derived from RGD as Potent Inhibitors of the Platelet Fibrinogen Receptor and Platelet Aggregation,”J. Med. Chem. 37(6): 769-780, 1994.
Beesley et al., “The post-synaptic density: putative in

Affiliated with

Also associated with

Rating

Compounds and methods for modulating apoptosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and methods for modulating apoptosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for modulating apoptosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3062651